- An early trial has shown significant promise for a targeted treatment, ozekibart, when combined with chemotherapy for patients with advanced bowel cancer.
- The drug works by mimicking a natural protein to trigger the 'death' of cancer cells while largely sparing healthy tissue.
- The Phase I trial, led by the Royal Marsden NHS Foundation Trust, involved 45 patients whose advanced bowel cancer had worsened after prior treatments.
- Results indicated that tumours shrank in 20 per cent of patients, and the cancer ceased growing in almost 87 per cent of participants.
- One patient, 59-year-old Amanda Burgess, described the therapy as giving her a “new lease of life”, allowing her to spend more time with her family and her beloved dogs.
IN FULL
